Andere talen Hua Medicine (Shanghai) Ltd.

Aandelen

2552

KYG4644K1022

Beurs gesloten - Hong Kong S.E. Andere beurzen 10:08:20 16-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,49 ^HKD	-2,61%		+1,36%	-24,37%

28/03	Hua Medicine (Shanghai) Ltd. Rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023	CI
2023	Hua Medicine (Shanghai) Ltd. Benoemt Yi Zhang tot uitvoerend bestuurder met ingang van 1 januari 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024	29/12
Hua Medicine Intends to Conduct Trials of Diabetes Drug in US	21/12
Hua Medicine Submits Investigational New Drug Application with the U.S. Food and Drug Administration for the 2Nd Generation Glucokinase Allosteric Activator	21/12
China Includes Hua Medicine's Type 2 Diabetes Medication in Drug Reimbursement List	14/12
Hua Medicine's Unit Receives 800 Million Yuan for Development of Diabetes Drug	22/11
Hua Medicine Ltd. Announces Board and Committee Changes	12-10-23
Hua Medicine Announces 2023 Interim Results	25-08-23
Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	24-08-23
Hua Medicine Signs Distribution Agreement with Digital Healthcare Platform	11-04-23
Hua Medicine Ltd. Announces Resignation of Mr. Junling Liu as Independent Non-Executive Director and Change in Composition of the Board Committees	31-03-23
Hua Medicine Shrinks Loss in 2022 as Revenue Witnesses a Boost	29-03-23
Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	29-03-23
Hua Medicine Makes 49 Million Yuan of HuaTangNing Sales Since Launch	17-02-23
Hua Medicine Receives 400 Million Yuan in Milestone Payments for Diabetes Treatment	08-02-23
Hua Medicine Ltd. Announces Directorate and Committee Changes	30-12-22
Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Director	24-11-22
Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company	18-11-22
China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares slipped 11%	10-10-22
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China	10-10-22

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Hua Medicine (Shanghai) Ltd.

Aandelen

2552

KYG4644K1022

Andere talen

Filters